Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PLEC | Q15149 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365062 | 0.90 | SRD5A2 (0.47) | SRD5A2SRD5A1TTRALDH1A1PTPRC | |
| SCHEMBL12365133 | 0.88 | SRD5A2 (0.43) | SRD5A2SRD5A1TTRALDH1A1PTPRC | |
| SCHEMBL12390256 | 0.86 | SRD5A2 (0.44) | SRD5A2SRD5A1TTRALDH1A1KDM4E | |
| SCHEMBL12365476 | 0.86 | PDK2 (0.42) | ALDH1A1KDM4EPTPRCLMNAHPGD | |
| SCHEMBL12365492 | 0.85 | SRD5A2 (0.43) | SRD5A2SRD5A1TTRALDH1A1MAPT | |
| SCHEMBL12364992 | 0.84 | SRD5A2 (0.49) | SRD5A2SRD5A1TTRALDH1A1KDM4E | |
| SCHEMBL12366817 | 0.83 | HTR2B (0.50) | — | |
| SCHEMBL12389853 | 0.83 | TTR (0.49) | SRD5A2SRD5A1TTRALDH1A1GAA | |
| SCHEMBL12365080 | 0.83 | SRD5A2 (0.50) | SRD5A2SRD5A1TTRALDH1A1KDM4E | |
| SCHEMBL12365007 | 0.82 | SRD5A2 (0.49) | SRD5A2SRD5A1TTRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SRD5A2 412/4885SRD5A1 247/4885TTR 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.